Pomalidomide-C6-PEG3-butyl azide is primarily used in the development of targeted cancer therapies. It serves as a key component in antibody-drug conjugates (ADCs), where it facilitates the precise delivery of cytotoxic agents to cancer cells. The compound’s azide group allows for efficient conjugation with antibodies or other targeting molecules through click chemistry, ensuring high specificity and minimal off-target effects. Additionally, its PEG3 linker enhances solubility and stability, improving the pharmacokinetic properties of the resulting therapeutic agents. This makes it a valuable tool in advancing personalized medicine and improving treatment outcomes for various malignancies.